Wegovy, a once-weekly injectable weight-loss medication, is now available in Australia. Designed for individuals with a BMI of 30 or more, Wegovy supports weight loss when combined with a reduced-calorie diet and increased physical activity. Learn how it works, its effectiveness, and potential side effects.
Wegovy may offer unexpected benefits beyond weight loss. A clinical trial revealed that individuals taking Wegovy during the COVID-19 pandemic had a 33% lower risk of dying from the virus compared to those on a placebo. The study, published in The Journal of the American College of Cardiology, also found a 19% reduction in overall mortality among participants on Wegovy. These results highlight the significant impact of treating obesity on life expectancy and suggest that Wegovy may offer protective effects against other infectious diseases.
Researchers are optimistic that GLP-1 agonists could eventually benefit a broader population with kidney disease.
KP.2 is one of several variants referred to as “FLiRT variants,” named after the specific mutations they possess.
Leading scientists warn that influenza is the pathogen most likely to spark a new pandemic soon.
Our sense of taste helps regulate the pace of our eating, and understanding this mechanism may lead to new approaches for weight loss.
Analysing the perception of obesity and the stigma surrounding weight-loss medication through a scientific lens.
The global rise in obesity has been accompanied by a rise in ultra-processed food consumption. Is this a coincidence?
Wegovy, initially approved for weight loss, has received approval for treating heart disease by the US Food and Drug Administration (FDA).
Wegovy, initially approved for weight loss, has received approval for treating heart disease by the US Food and Drug Administration (FDA).
